Therapeutic application of genome editing technologies (e.g. CRISPR-Cas9) for human disease attracts attention. In parallel with increased preclinical evidence of therapeutic benefit, unintended genome edits are reportedly a potential risk.
Areas of interest:
Drug-induced vascular injury (DIVI) is a significant cause of termination of candidate drugs in nonclinical safety assessment, because methodology to predict or monitor the onset of DIVI in nonclinical or clinical is not established. Hence, DIVI in nonclinical safety assessment can be an obstacle to the further development of candidates.
We are seeking your ideas which can be anticipated to aid the identification and translational monitoring system for DIVI, especially focusing on the endothelial progenitor and/or stem cells
Drug induced neurotoxicity in experimental animals is a critical issue in the continuation of drug development, especially if neuronal necrosis is noted. To proceed with compound development, investigational studies for toxicity mechanism, species differences of sensitivity or human relevancy are essential. We are interested in assay developments for bridging drug induced neurotoxicity in animals to those in human.
Recent developments of novel targeted therapies are contributing to the increased long-term survival of cancer patients; however, drug-induced cardiotoxicity induced by cancer drugs remains a serious problem in clinical settings. Especially, Cardio-oncology, the intersection of heart conditions in patients who have been treated for cancer, is a focus of attention in drug development. To develop safer cancer drugs in pre-clinical studies, we seek ideas for assays or technologies to estimate drug-induced risks in advance.
Serious adverse events (SAE) often occur with individual differences. However, few models recreate individual differences in drug susceptibility.
To overcome this issue, we are seeking proposals that can recreate individuals’ different susceptibilities to a drug-induced SAE using bacterial flora such as enterobacterium and dental bacterium.
Recently human body odour has been proven to vary in relation with health disorders. Especially, biomimetic approaches such as dog's olfactory senses were reported as powerful tools to detect disease that is not clinically evident. However, there are few reports about using odour sensors to monitor drug safety as biomarkers. We are seeking ideas for technology to monitor drug safety biomarkers using odour sensors.
Follow the procedure below to make an application.
After submission, your website will show the “Submission Completed” page and you will receive a confirmation email.
Please contact the COCKPI-T® Funding Office for further information.
* Please be aware that we may not be able to respond to every inquiry.